BDTX-1535 is an orally bioavailable, brain penetrating, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, mutant-selective EGFR inhibitor BDTX-1535 selectively targets, irreversibly binds to, and inhibits the activity of various EGFR alterations and mutations, including certain intrinsic and acquired resistance mutations. This prevents EGFR-mediated signaling in susceptible tumor cells. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

 

Brand: BCM

 

Targets: EGFR

 

Boiling Point: 730.0±60.0 °C(Predicted)

 

pKa: 11.44±0.43(Predicted)

 

Solubility: Soluble in DMSO.

 

Isomeric SMILES: CN1C[C@H]2C[C@]2(C1)C#CC3=CC4=C(C=C3NC(=O)/C=C/CN5CCOCC5)C(=NC=N4)NC6=C(C(=CC=C6)Cl)F  

 

InChIKey: LMOVDLRMIRLIJF-TUVXKDNKSA-N  

 

InChI: InChI=1S/C30H30ClFN6O2/c1-37-17-21-16-30(21,18-37)8-7-20-14-26-22(29(34-19-33-26)36-24-5-2-4-23(31)28(24)32)15-25(20)35-27(39)6-3-9-38-10-12-40-13-11-38/h2-6,14-15,19,21H,9-13,16-18H2,1H3,(H,35,39)(H,33,34,36)/b6-3+/t21-,30+/m1/s1

 

Attribute
[Chem Name]	(2E)-N-[4-[(3-Chloro-2-fluorophenyl)amino]-7-[2-[(1R,5S)-3-methyl-3-azabicyclo[3.1.0]hex-1-yl]ethynyl]-6-quinazolinyl]-4-(4-morpholinyl)-2-butenamide
[Synonym]	BDTX-1535; BDTX 1535; BDTX1535
[CAS No.]	2607829-38-7
[Formula]	C30H30ClFN6O2
[Molecular]	561.0584
[Form]	Solid powder
[Storage]	Room temperature for months, or -20ºC for 3 years.

Goods Tag